China-Biotics continues probiotics growth
This article was originally published in The Tan Sheet
Executive Summary
New retail products sold in the firm's Shining outlets helped drive net sales up 35.5 percent to $15.4 million in the first quarter of fiscal 2010. Shanghai-based China-Biotics reported Aug. 17 that net income for the April-June also rose significantly, to $5.8 million from $3.2 million. Quarterly earnings per share grew to 34 cents from 19 cents, the firm said. Looking ahead, the probiotics manufacturer intends to slow retail expansion as it readies a new facility to begin trial production of bulk additives in its second quarter (1"The Tan Sheet" July 20, 2009). China-Biotics added it applied in July for patents for four probiotics-based yogurt products with China's State Intellectual Property Office and anticipates receiving patent certificates in about two years
You may also be interested in...
Sales & Earnings In Brief
Currency exchange hits Abbott nutritionals: Negative effects from currency exchange help drive down Abbott Nutrition's international revenues from nutritional products by 1.9 percent to $615 million in the firm's fiscal 2009 second quarter, even as U.S. sales grow 10 percent to $668 million. The Abbott Park, Ill.-based company July 15 said a 10.3 percentage point loss from currency exchange slowed nutritional revenues. Its worldwide nutritional sales increased 4 percent despite an unfavorable 5.2 percent effect of exchange rates to $1.28 billion for the April-June period. A 12 percent surge in adult products drove U.S. nutritionals growth to $326 million. Internationally, pediatric formulas continued expanding, growing 3.6 percent, including exchange rate effects, to $354 million. John Thomas, VP of investor relations, said during a same-day earnings call that Abbott expects to launch next-generation Similac and Gain infant formulas in eight more countries this year. He said the reformulated Similac formula and its user-friendly packaging "have been very well received" by customers (1"The Tan Sheet" March 23, 2009)
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.